Royalty Pharma (RPRX) FCF Margin (2019 - 2026)
Royalty Pharma (RPRX) posted FCF Margin of 42.16% for Q1 2026, up 180.59% sequentially from 15.03% in Q4 2025, and down 6255.0% YoY from 0.69% in Q1 2025.
Royalty Pharma (RPRX) FCF Margin (2019 - 2026) Analysis & Trends
Royalty Pharma has reported FCF Margin for 8 years, with the latest figure at 42.16% in Q1 2026.
- Quarterly FCF Margin fell 6255.0% year-over-year to 42.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18.97% (up 661.0% YoY) and the FY2025 annual result came in at 33.31%, up 2168.0% from the prior year.
- FCF Margin advanced to 42.16% in Q1 2026 per RPRX's latest filing, from 15.03% in the prior quarter.
- Over five years, FCF Margin peaked at 104.71% in Q1 2025 and troughed at 135.58% in Q3 2022.
- A 5-year average of 26.58% and a median of 42.16% in 2026 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin jumped 15840 bps in 2023, then slumped 11481 bps in 2024.
- Over 5 years, FCF Margin stood at 56.51% in 2022, then plunged by 168 bps to 38.52% in 2023, then jumped by 208 bps to 41.46% in 2024, then plunged by 64 bps to 15.03% in 2025, then surged by 181 bps to 42.16% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 42.16%, 15.03%, and 42.55% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -18,629.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.82% |
| Mar 31, 2026 | 42.16% |
| Dec 31, 2025 | 15.03% |
| Sep 30, 2025 | -42.55% |
| Jun 30, 2025 | 62.71% |
| Mar 31, 2025 | 104.71% |
| Dec 31, 2024 | 41.46% |
| Sep 30, 2024 | -86.94% |
| Jun 30, 2024 | -13.11% |
| Mar 31, 2024 | 101.86% |
| Dec 31, 2023 | -38.52% |
| Sep 30, 2023 | 22.82% |
| Jun 30, 2023 | 101.70% |
| Mar 31, 2023 | 63.18% |
| Dec 31, 2022 | 56.51% |
| Sep 30, 2022 | -135.58% |
| Jun 30, 2022 | 74.62% |
| Mar 31, 2022 | 81.88% |
| Dec 31, 2021 | 55.28% |
| Sep 30, 2021 | -147.88% |